Advertisement

Burden of Cancer in Serbia

  • H. Vlajinac
  • S. Sipetic-Grujicic
  • S. Jankovic
  • L. Markovic-Denic
  • J. Marinkovic
Reference work entry

Abstract:

The morbidity and mortality of cancers have a major impact on the population of Serbia. During 5-year period (1999–2003), the average standardized  incidence rates for all cancers (all sites but non-melanoma skin cancer) were 241.9/100,000 for men, and 215.4/100,000 for women. In men, the most frequent was lung cancer, followed by colorectal, prostate, bladder and stomach cancers. In women, the incidence was highest for breast cancer, followed by cervical, colorectal, lung and corpus uteri cancers. The average standardized  mortality rates for the same period were 159.5/100,000 for men, and 106.4/100,000 for women. In men the highest mortality rates were for lung cancer, followed by colorectal, stomach and prostate cancers. In women, breast cancer was on the first place as a cause of death followed by lung cancer, colorectal, cervical and stomach cancers. Stomach, colorectal, lung, breast and cervical cancers were responsible for 73,197 (19.9/1,000 population) disability adjusted life years – DALYs in men and for 60,482 (15.6/1,000) DALYs in women, on a yearly basis. The participation of years of life lost from premature mortality ( YLL) in  DALY was 95.2% in men and 93.2% in women. The greatest part of the DALY was caused by lung cancer in men and by breast cancer in women. During the period 1985–2002 in Serbia, there was a significant rise in the mortality from overall cancers, and among the most frequent cancers, for lung, breast and cervical cancers. The increase in lung cancer mortality rates was more pronounced in women. Increasing cancer mortality trends stress the importance of implementing preventive measures that have proved effective in other countries, especially  screening for cervical cancer, the incidence of which in Serbia (25.8/100,000) was the highest in Europe.

Keywords

Cervical Cancer Cancer Mortality Tobacco Control Stomach Cancer Lung Cancer Mortality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:

DALY

disability adjusted life years

EURO

European countries

MR: IR

mortality rate: incidence rate (mortality to incidence rate ratio)

YLL

years of life lost

YLD

years lived with disability

References

  1. Adanja B, Gledovic Z, Pekmezovic T, Vlajinac H, Jarebinski M, Zivaljevic V, Pavlovic M. (2000). Dig Liver Dis. 32: 386–391.PubMedCrossRefGoogle Scholar
  2. Ahmad OB, Boschi-Pinto C, Lopez A, Murray CJ, Lozano R, Inoue M. (2000). Age Standardization of Rates. A New WHO Standard. GPE Discussion Paper Series No. 31. World Health Organization, Geneva.Google Scholar
  3. Alberg AJ, Samet JM. (2003). Chest. 123: 21S–49S.PubMedCrossRefGoogle Scholar
  4. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. (2005). Int J Epidemiol. 34: 405–412.PubMedCrossRefGoogle Scholar
  5. Antunes JL, Toporcov TN, de FP. Andrade (2003). Eur J Cancer Prev. 12: 367–372.PubMedCrossRefGoogle Scholar
  6. Arbyn M, Raifu AO, Autier P, Ferlay J. (2007). Ann Oncol. 18: 1708–1715.PubMedCrossRefGoogle Scholar
  7. Atanasković-Markovic Z, Bjegović V, Janković S, Kocev N, Laaser U, Marinković J, Marković-Denić L, Pejin-Stokić Lj, Penev G, Stanisavljević D, Šantrić-Milićević M, Šaulić A, Šipetić-Grujičić S, Terzić-Šupićz, Vlajinac H. (2003). The burden of disease and injury in Serbia (Ministry of Health of the Republic of Serbia, Belgrade) Available online at: www.sbds.sr.gov.yu.
  8. Boyle P, Ferlay J. (2005). Ann Oncol. 16: 481–488.PubMedCrossRefGoogle Scholar
  9. Bray F, Carstensen B, Møller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E. (2005a). Cancer Epidemiol Biomarkers Prev. 14: 2191–2199.PubMedCrossRefGoogle Scholar
  10. Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Møller H, Hakama M, Parkin DM. (2005b). Cancer Epidemiol Biomarkers Prev. 14: 677–686.PubMedCrossRefGoogle Scholar
  11. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. (2005). Int J Cancer. 113:1005–1009.PubMedCrossRefGoogle Scholar
  12. Chu KC, Tarone RE, Chow WH, Hankey BF, Ries LA. (1994). J Natl Cancer Inst. 86: 997–1006.PubMedCrossRefGoogle Scholar
  13. Chu KC, Tarone RE, Freeman HP. (2003). Cancer. 97: 1507–1516.PubMedCrossRefGoogle Scholar
  14. Cookson M. (2001). JMCC. 8:133–140.Google Scholar
  15. Ferlay J, Bray F, Pisani P, Parkin DM. (2004). Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0: IARC Cancer Base no. 5. IARC Press, Lyon.Google Scholar
  16. Gustafsson L, Pontén J, Bergström R, Adami HO. (1997). Int J Cancer. 71: 159–165.PubMedCrossRefGoogle Scholar
  17. Heresbach D, Manfredi S, D `halluin PN, Bretagne JF, Branger B. (2006). Eur J Gastroenterol Hepatol. 18: 427–433.PubMedCrossRefGoogle Scholar
  18. Institute of Public Health of Serbia. (2001–2005). Cancer Registry of Central Serbia. Incidence and Mortality in Central Serbia, Report no. 1–5. Institute of Public Health of Serbia, Belgrade.Google Scholar
  19. Jensen OM, Parkin DM, Lennan R, Muir CS, Skeet RG. (1991). Cancer Registration: Principles and Methods. IARC, Lyon.Google Scholar
  20. Jevremovic I, Jankovic S, Markovic-Denic L, Radosavljevic V, Radovanovic Z. (1994). Vojnosanit Pregl. 51: 114–117.PubMedGoogle Scholar
  21. Kamangar F, Dores GM, Anderson WF. (2006). J Clin Oncol. 24: 2137–2150.PubMedCrossRefGoogle Scholar
  22. Kwiatkowski M, Huber A, Moschopulos M, Lehmann K, Wemli M, Häfeli A, Recker F. (2004). Swiss Med Wkly. 134: 580–585.PubMedGoogle Scholar
  23. Levi F, Bosetti C, Fernandez E, Hill C, Lucchini F, Negri E, La Vecchia C. (2007). Int J Cancer. 121:462–465.PubMedCrossRefGoogle Scholar
  24. Levi F, Lucchini F, Gonzalez JR, Fernandez E, Negri E, La Vecchia C. (2004a). Ann Oncol. 15: 338–345.PubMedCrossRefGoogle Scholar
  25. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. (2004b). Prostate. 60: 46–52.PubMedCrossRefGoogle Scholar
  26. Levi F, Lucchini F, Negri E, La Vecchia C. (2004c). Cancer. 101: 2843–2850.PubMedCrossRefGoogle Scholar
  27. Levi F, Lucchini F, Negri E, Zatonski W, Boyle P, La Vecchia C. (2004d). Ann Oncology. 15: 1425–1431.CrossRefGoogle Scholar
  28. Markovic-Denic L, Zivkovic S, Sipetic S, Vlajinac H, Kocev N, Marinkovic J. (2006). Soz Praventiv Med. 51: 117–122.CrossRefGoogle Scholar
  29. Ministry of Health, Republic of Serbia. (2007). National Health survey, Serbia 2006. Ministry of Health, Republic of Serbia, Belgrade.Google Scholar
  30. Murray CJ, Lopez AD (ed.). (1996). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Global Burden of Diseases and Injury Series, Vol. 1. Harvard University Press, Cambridge.Google Scholar
  31. Murray CJL, Lopez AD, Mathers CD, Stein C. (2001). The Global Burden of Disease 2000 Project: Aims, Methods and Data Sources. World Health Organization, Geneva.Google Scholar
  32. Murray CJL, Salomon JA, Mathers CD, Lopez AD (ed.). (2002). Summary Measures of Population Health: Concepts, Ethics, Measurement and Applications. World Health Organization, Geneva.Google Scholar
  33. Parkin DM, Bray F, Devesa SS.(2001). Eur J Cancer. 37: S4–S66.PubMedCrossRefGoogle Scholar
  34. Parkin DM, Bray F, Ferlay J, Pisani P. (2005).CA Cancer J Clin. 55:74–108.PubMedCrossRefGoogle Scholar
  35. Post PN, Straatman H, Kiemeney LA, Coebergh JW. (1999). Int J Epidemiol. 28: 403–408.PubMedCrossRefGoogle Scholar
  36. Quinn M, Babb P. (2002). BJU Int. 90: 162–173.PubMedCrossRefGoogle Scholar
  37. Roemer R, Taylor A, Lariviere J. (2005). Am J Public Health. 95: 936–938.PubMedCrossRefGoogle Scholar
  38. Shapiro S, Coleman EA, Broeders M, Codd M, de Koning H, Fracheboud J, Moss S, Paci E, Stachenko S, Ballard-Barbash R. (1998). Int J Epidemiol. 27: 735–742.PubMedCrossRefGoogle Scholar
  39. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJL. (2002). BMC Cancer. 2: 37–63.PubMedCrossRefGoogle Scholar
  40. Tsugane S, Sasazuki S. (2007). Gastric Cancer. 10: 75–83.PubMedCrossRefGoogle Scholar
  41. Vlajinac H, Adanja B, Jarebinski M. (1990). Medicinska istrazivanja 23: 73–76.Google Scholar
  42. Vlajinac H, Marinkovic J, Kocev N, Adanja B, Sipetic S, Pekmezovic T, Zivaljevic V. (2000). Srp Arh Celok Lek. 128: 309–315.PubMedGoogle Scholar
  43. Vlajinac H, Sipetic-Grujicic S, Jankovic S, Marinkovic J, Kocev N, Markovic-Denic L, Bjegovic V. (2006). Croat Med J. 47: 134–141.PubMedGoogle Scholar
  44. Wun LM, Feuer EJ, Miller BA. (1995). Cancer Causes Control. 6: 135–144.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • H. Vlajinac
  • S. Sipetic-Grujicic
  • S. Jankovic
  • L. Markovic-Denic
  • J. Marinkovic

There are no affiliations available

Personalised recommendations